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Abstract
Clusters are important for regional economies and emergent clusters are in a key 
position, as a means of adding more diversification to the current economic activity 
by involving new technologies and industries. Science-based industries may be the 
most promising in this regard since they are encouraged to develop and enhance 
the economic imaginaries of territories under the umbrella of radical innovations or 
in the name of broadening the current economic model based on mostly traditional 
industries. Regenerative medicine (RM) could be an example of these so-called 
emergent clusters. Regenerative medicine is highly dependent on academic research, 
which means that local territories must fund the research in this field and, hence, 
they expect some returns as well. As territories do not typically have existing 
industries specifically in RM, these industries must emerge or expand from existing 
ones. Regenerative medicine involves a wide spectrum of different technologies and 
industries that are likely to form a cluster and benefit from it if successfully developed. 
The first aim of this paper is to show how some obstacles eventually impede the proper 
development of these emergent clusters. The second aim is to shed light on how 
innovations emerge in the cluster and what are the main implications for the territory. 
In this study, existing literature is used in order to describe the technology market and 
commercial aspects of the RM sector. Empirically this study is based on the emergent 
RM cluster in the region of Tampere in Finland. Analysis of 24 conducted interviews 
helps to contextualize the emergence of the RM cluster in Tampere, where academia 
is both the booster and the driver of the emergent RM cluster. Commercialization of 
research in the RM field is one of the goals at the university, even though there are 
no commercial outcomes yet available. This study contributes to the understanding 
of emergent cluster development in science-based industries in their embryonic and 
early stages. Major challenges are pointed out in an emergent cluster that calls for 
tailor-made socio-economic policies at the meso-level. Tailored policies matter in 
science-based clusters, and specific sectors in specific stages of development need 
specific policies in order to become matured clusters.
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Introduction
Clusters are important for regional economy as they include different 
industries working together (Saxenian, 1994). Many traditional clusters 
e.g. textile, IT, automotive, food, energy, etc., include matured industries 
(Iammarino & McCann, 2006). As scientific development in universities 
goes forward, there may be possibilities to create new industries and even 
new clusters, as many different technologies are often needed in order to 
fully exploit scientific research (Stoerring, 2007; Stoerring & Dalum, 2007). 
In this study, the regenerative medicine (RM) sector is used as an example 
of a new emergent science-based cluster (Pavitt, 1984). Globally in the RM 
sector, commercial development is only in its early stage, and innovation 
is dependent on academia, research centres and hospitals (McMahon & 
Thorsteinsdottir, 2013). The future of the RM sector is highly dependent on 
university-based research, overcoming the financial gap, and the emergence 
of firms, and in the process of RM sector development, hospitals play a 
significant role as an endpoint of therapies. 
Conceptually this study contributes to the cluster life cycle theory by 
discussing the commercial engine that enables growth and introducing some 
empirical evidence from the very early phase of a cluster life cycle. As clusters 
tend to speed up innovation, firm creation and growth (Baptista & Swann, 
1998), new sectors like RM would presumably benefit clustering. However, 
due to the small number of commercial entities globally in the RM sector, 
it is not possible to study matured clusters and their early phases. Instead, 
an emergent science-based RM cluster in the Tampere region provides an 
opportunity to scrutinize the very early phases of a potential cluster ex ante. 
As a result of university-based innovations, it might be possible to see the 
emergence of new firms and the growth of existing firms who expand their 
product or service portfolio to the RM sector.
The first aim of this study is to show how some obstacles eventually 
impede the proper development of these emergent clusters in the RM sector. 
As the development of commercial RM products costs significantly and takes 
a long time, firms need to overcome these challenges. The second aim is 
to shed light on how innovations emerge in the cluster and what are the 
main implications for the territory. To answer these questions, a case study 
was conducted in Tampere, Finland. In Tampere, RM-related innovations are 
developed in academia with great hope for future economic growth, in terms 
of new firms, expansion of existing firms, and employment.
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Cluster view on RM
The study of clusters as research objects traces its roots back to the 1990s 
(Porter, 1990). The main motivation for cluster analysis is to understand 
how a country/region (or whatever the level is being talked about) gains the 
competitive advantage of related sectors embedded in a region compared 
with other global competitors or other lower-scale (local) territories. However, 
studies on these matters have confirmed the existence of more appropriate 
conceptual frameworks, mainly from the innovation studies community, 
where technological change is included as one of the cornerstones to explain 
the dynamics of the sector. Another dimension included in the innovation 
systems framework is the multi-level perspective (Geels, 2002), in order to 
understand the correlation of the forces between actors (distributed agency) 
at different territorial levels (international, national, regional and local). 
Among different models proposed by innovation scholars, in this article we 
used as a theoretical background (Figure 1) the model of innovation system 
proposed by Arnold and Kuhlmann (2001). These authors propose a model 
that not only shows but also emphasizes the important aspect of demand 
affecting both industry and university, and is divided into final demand and 
intermediate demand. Political sphere influences are also analysed under 
this framework by including both government and policies that affect 
brokers between universities and industry, supporting infrastructure, and 
universities. In summary, three elements are present within this framework: 
1) a set of institutions, which promote and enable innovations to occur; 
2) the interactions between those above-mentioned players; and 3) the 
environmental conditions within which the system works. This functional 
view on innovation systems is treated in the work of Hekkert et al. (2007).
Figure 1. Theoretical framework modified from Kuhlmann and Arnold (2001) 
Source: Original framework was presented in the order Arnold and Kuhlmann in the publication Kuhl-
mann and Arnold (2001).
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Demand is an important aspect of the emergent cluster and in the RM 
sector it is quite complex. Is the customer a patient who gets treatment, the 
society who benefits from healthier people, or a hospital, which delivers the 
treatment? As in any sector, depending on the business strategy, firms produce 
different products at different points of the supply chain – for example, a firm 
producing compounds as a supplier, a hospital delivering generated bone to 
the patient, or a firm utilizing stem cells in a gene therapy. The other thing 
is that innovation requires different competencies in different phases. For 
this reason, Eliasson and Eliasson (1996) developed the competence bloc 
theory, which is a good starting point to evaluate the needed competencies 
for economic growth and successful innovations from both a business and 
innovation point of view, as the competence bloc is the infrastructure needed 
to create, select, recognize, diffuse and exploit new business ideas (Table 1). 
Eliasson and Eliasson (1996) argued that in the emerging biotechnology sector 
sustainable economic growth would be reached through entrepreneurs 
funded by venture capitalists, and winners later acquired by established 
companies acting as industrialists. It thus calls the human competencies 
that are needed to create new businesses and industrial success (Eliasson & 
Eliasson, 1996). This also describes the dynamics in the emergent science-
based cluster. As universities are innovators, entrepreneurs are needed to 
carry emerging innovations forward. Competence bloc theory also implies 
that enough entrepreneurs are located in the territory so that venture 
capitalists are able to recognize those that are most viable ones. Those firms 
that are not viable will be terminated fast so that they have an opportunity 
to select another potential innovation to work on.
Table 1. Actors of competence bloc
Actors Tasks Function in infrastructure
Customer
Active, competent and resourceful. 
Products are never better than 
customers are capable of demanding.
Demand
Innovator Connects technical specializations. Creation
Entrepreneur Selects commercially potential 
innovations.
Selection
Venture capitalist Recognize and finance commercially 
viable opportunities.
Recognition
Industrialists, business 
leaders and financial 
experts
Bring new product to full-scale 
production.
Exploitation
Exit-market Expectation for reasonable or better 
profit for those who are successful.
Incentive
Source: Eliasson and Eliasson, (1996).
 143 Tuomo Heinonen, Francisco Javier Ortega-Colomer /
Journal of Entrepreneurship, Management and Innovation (JEMI), 
Volume 11, Issue 4, 2015: 139-158
The cluster life cycle follows four phases: formation, development, 
maturity and renewal/decline (Belussi & Sedita, 2009). First firms are 
established in the formation phase, followed by a significant growth in 
the firm population in the development phase. Maturity comes when firm 
population is stabilized. The competence bloc is especially important in the 
formation phase of the cluster and its subsequent development phase. In 
the biotechnology-related industries, start-ups tend to be those that develop 
innovations and established companies bring those new products to full-
scale production. If needed competencies are not available, it is not likely 
that the development phase of the cluster will continue very far, if it begins 
at all. As the cluster grows (development phase), local firms are also able to 
innovate and that way expand their product offerings. At this point, the locus 
of activity in the emergent cluster shifts from academia to firms, even though 
academia and hospitals have important roles in creating new knowledge, 
innovations, being the places for clinical trials, and act as end-users.
Data and method
Empirical insights in this study are based on a single case study conducted 
in Tampere, Finland. Although it would have been more desirable to include 
more case studies in the research, the quest for a pluralist approach and a 
deep perspective allowed us to conduct only a single case study (Yin, 1989). 
This obviously does not support generalizability, but ensures a richer look at 
one emergent phenomenon on a global scale (Marshall & Rossman, 1999). 
The major share of interviews were conducted at the Institute of Biosciences 
and Medical Technology (BioMediTech), which is a joint institute of the 
University of Tampere and Tampere University of Technology. In BioMediTech, 
the Human Spare Parts research programme was the focus, as it is focusing 
on RM therapies and technologies. This article emphasizes the emergence 
of a cluster, which has its roots in the university level. The science-based 
cluster is in the formation phase, which means that no firms have emerged 
yet. Thus, inclusion of more firms in the interviews is not plausible and 
instead interviews focused to the university. Altogether 24 interviews were 
conducted (Table 2), and in all of the interviews the same semi-structured 
set of questions was used within the following main themes: research, 
entrepreneurship, venture finance, legitimization, market formation, hospital 
environment, and end-value. As a result these interviews gave a coherent 
view of how different actors at different levels understand the emergent RM 
cluster in Tampere. Other sources for information were relevant documents, 
articles and news that were used to describe the history of this emergent RM 
cluster as well as the industrial sphere. 
144 / Regenerative Medicine as an Emergent Cluster in Tampere Region
The Process of Firm Growth
Marta Gancarczyk, Jon Mikel Zabala-Iturriagagoitia (Eds.)
Table 2. Conducted interviews, organizations and organization level
Organization
Number of 
interviews Level
BioMediTech (University) 15 Local
University Hospital of Tampere 3 Local
Firm 1 Local
Regional development agencies 2 Regional
Ministry of Employment and the Economy 2 National
The Finnish Funding Agency for Technology and Innovation 1 National
Elements of the emerging RM sector with an impact on industrial 
development
In human healthcare, there have traditionally been two main disciplines: 
medicine and surgery (Polak et al., 2010) and RM could be a third one 
attempting to revolutionize healthcare. A short, simple definition of RM is 
provided by Mason and Dunnill (2008a: 4): ‘Regenerative medicine replaces 
or regenerates human cells, tissue or organs, to restore or establish normal 
function’. Hence, RM uses medicine, surgery, and other disciplines as 
a multi-disciplinary field (Polak et al., 2010), and even though it is mostly 
based on cell therapy, i.e. the expected fourth pillar of the healthcare sector 
alongside pharmaceuticals, biopharmaceuticals and medical devices (Mason 
& Manzotti, 2009), it consists of a wide spectrum of different approaches and 
technologies. The set of potential industries is quite wide and is organised in 
different levels regarding the supply chain; for example, a firm that decides 
to concentrate on regenerative compounds is most probably a supplier to 
a firm concentrating on tissue engineering. Also hospitals are important for 
progress in RM because they provide the infrastructure for surgery and care 
of patients, but also ideas regarding current needs where RM therapies might 
help.
Major expectations for the RM sector are based on the use of stem cells. 
The biggest hurdle for the use of stem cells derived from human embryos is 
the ethical and political environment (Harvey, 2010) and in some EU countries 
it is not possible to have a patent relating to human cells derived from 
embryos (Mason & Dunnill, 2008b). In general, there are currently different 
laws among the nations in the EU and the US regarding the use of embryos 
(Mason & Dunnil, 2008b). With induced pluripotent stem cells (iPSC), found 
in 2006, it might be possible to overcome these hurdles and thus generation 
of iPSCs might have a major impact on RM (Amabile and Meissner, 2009). 
However, there are concerns if iPSCs are identical to embryonic stem cells and 
if not, what is the level of similarity for therapeutic and screening purposes? 
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Thus there are some challenges to be met before iPSCs can be used routinely 
in pharmacological screening and RM (Amabile & Meissner, 2009).
According to Martin et al. (2006), there were two waves of 
commercialisation and industry building in the RM sector – the first was 
between the 1980s and the 1990s, and a second wave from the mid-1990s 
onwards. In the first wave, the U.S. dominated, but in the second wave, 
Europe has established a stronger presence. According to Mason (2007), 
the problem is that funding in the RM sector (somewhere around 2005) has 
switched from venture capital and pharmaceutical firms to public finance, 
philanthropists and military products. Venture capitalists are not interested 
in investing in firms until later phases of the clinical trials (Parson, 2008). 
However, start-ups need funding for research, development, small-scale 
manufacturing, and early clinical trials (Mason & Dunnil, 2008b). Parson 
(2008) believes that for the majority of firms the future will depend on the 
possibility of moving forward from start-up-funds to later stage funds to 
sustain their products through clinical trials. For making this possible, one of 
the most relevant needs start-up companies in the RM sector is a competent 
management group (Johnson et al., 2011). However, Parson (2008) points out 
the limits of a start-up company in the RM sector, where a large amount of 
cells are needed for treatment in a large patient population and a small start-
up company may not be large enough to conduct the required trials. Hence, 
another strategy for an entrepreneurial firm is to be acquired by a bigger 
company, which is a possibility for a venture capitalist to exit the company if 
involved, and the established company as an industrialist continues to bring 
the product to full-scale production. 
Metcalfe et al. (2005) made an important point about the sustainability 
of the new technology and its requirements. According to them, commercial 
investments are sustainable only if there is a possibility of obtaining 
a necessary return from the market, and from this point of view, the 
development of demand and the role of regulation in establishing demand 
are both important. However, if the market is not fully established, technology 
development can be supported by non-commercial investment and instead 
of a technology ‘pull’, the only option that is left is to try technology ‘push’ 
with university based research.
For the companies in the RM sector it is important to have access to 
cutting edge research (Prescott, 2011). Academia and firms have several 
innovation co-operation activities, e.g. funding, licensing, consulting 
and advising between the scientific and technological networks in tissue 
engineering (Murray, 2002), and scientists with new ideas even have roles 
in RM firms bringing human and social capital with them (Murray, 2004). 
However, universities are expected to nurture innovation further in clinical 
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trials before establishing start-ups and obtaining venture capital for it; some 
countries are actually filling this gap by establishing government centres for 
funding cell therapy clinical trials (Mason et al., 2011).  In Finland this is not 
the reality yet.
Hellman et al. (2011) argued about the need for collaborative interactions 
between scientists, physicians, investors, attorneys, regulators, political 
entities and patients in building a biomedical industry. The RM sector will need 
highly specialized hospitals and day-care centres where cells are implanted 
and therapies conducted, and thus, training for the clinical community must 
be conducted in order to be able to use products (Mason & Dunnil, 2008b). 
Regulatory bodies, though, are not always up to date about biomedical 
scientific understanding and possibilities of technology, and thus there are 
examples of evolutionary trajectories where regulation has co-evolved with 
innovation sequence and the market (Metcalfe et al., 2005).
Salter et al. (2014) make a distinction between different models in stem 
cell therapies (Table 3). Model I is the only solid scientific innovation model 
while the rest are so called medical innovation models. Medical innovation 
in cell therapy is defined the followed way: ‘Medical innovation in cellular 
therapy may be viewed as ethical and legitimate use of non-approved cell 
therapy by qualified healthcare professionals in their practice of medicine’ 
(Gunter et al., 2010, p. 966). The goal of medical innovation in cell therapy is 
always to be beneficial for the individual patient while the goal of scientific 
innovation is to obtain generalizable results (Lindvall & Hyun, 2009). 
Table 3. Differences between stem cell innovation models 
 Model I Model II Model III Model IV
Scientific 
/ medical 
innovation
Scientific 
innovation
Medical 
innovation 
(Western)
Medical 
innovation (non-
Western)
Medical and 
scientific 
innovation
Regulation Traditional with 
clinical trial, 
advanced therapy 
medicinal product 
(ATMP) in EU
ATMP Hospital 
exemption
Not regulated Not regulated / 
traditional with 
clinical trial
Patient # Unlimited Single / small 
group
Large population Large population
Product Clinical application Non-routine 
exercise
Clinical application Clinical application
Ethics Knowledge 
generation
Patient benefit Patient benefit Patient benefit
Acting 
professional
Scientist Clinician Clinician Scientist / clinician
Source: Salter et al. (2014).
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Gunter et al. (2010) claimed that those patients not eligible for controlled 
clinical trials should be able to choose unproven but scientifically validated 
cell therapy options. In addition, it is said that it is not optimal to develop 
stem cell therapies only via the medical innovation pathway alone (Lindvall 
& Hyun, 2009). Thus, there might be a place for scientific and medical 
innovation paradigms in the cell therapy sector, if researchers are competent 
and patients are truthfully and ethically informed (Gunter et al., 2010). 
Currently in developed countries, it is almost impossible to bring new 
therapies to clinical use without any regulatory approval, as long as there 
is medical technology innovation involved. There are some exceptions, e.g. 
advanced therapy medicinal product (ATMP) Hospital Exemption in EU, which 
allows hospitals to do some clinical treatment without any clinical trials, but 
in these cases, treatment has to be non-routine treatment and regulatory 
authority has to approve it. Another problem is that there is no scientifically 
proven evidence that a product is efficient and safe. The other questions are 
whether these non-routine treatments can be understood as a new medical 
practice and what their role is in the development of the RM sector. With 
accumulated expertise, it is possible to serve patients, but it means that 
because of the ATMP Hospital Exemption regulation, treatments have to be 
conducted in the granted country and due to non-routine treatment not all 
who want to get it are eligible. Thus, regulation restricts medical innovation 
in very fundamental way, but also makes it safer.
Emergent RM cluster in Tampere
History
Biomaterial research has a long history in Tampere. Already in the 1980s there 
was advanced research in biomaterials, and researchers were able to develop 
a bio-absorbable screw to repair bone fractures (Sotarauta & Mustikkamäki, 
2015). Two decades later researchers in Tampere were able to grow real bone 
tissue from patients’ own stem cells. This progress and development did not 
happen in a vacuum, but included several organizations and programmes. 
One of the steps forward with regard to the RM sector in the Tampere region 
was the establishment of BioneXt Tampere (2003–2010). This organization 
was established in order to support tissue engineering, biomaterials, bio-ICT 
and immunology fields in acquiring needed expertise and investments. 
Several organizations in Tampere established Regea in 2005 as a research 
institute with a focus not only on basic research but especially on clinical 
applications. One of the successes at that time was that the city of Tampere 
endowed a professorship for stem cell research to Regea. According to 
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interviewee: “the vision was from the beginning that this research generates 
commercial outputs”. Indeed, only two years after the establishment of Regea 
they were able to conduct an operation with a real patient, in which a part of 
the patient’s missing jawbone was reconstructed with stem cells taken from 
the patient’s own fatty tissue. Over the ensuing years, this therapy has been 
used successfully in over 25 patients in cooperation with Finnish university 
hospitals, and lately in Tampere. Before the establishment of Regea, a good 
manufacturing practices (GMP) level laboratory in the University of Tampere 
was crucial in the development of the clinical tissue engineering application.
Some other initiatives also built a basis for the formation phase of the RM 
cluster in Tampere. The Biosensing Competence Centre (2007–2010) focused 
on regional strengths of tissue engineering and clinical diagnostics, and 
the national programme HealthBIO (2007–2013) focused and contributed 
to the biotechnology field in Tampere. HealthBIO was a biotechnology 
cluster focused on utilizing high competence in business and on developing 
supporting structures. In 2011, the University of Tampere and Tampere 
University of Technology established BioMediTech as a successor to Regea. 
BioMediTech continued the prospective stem cell research and the Finnish 
Funding Agency for Technology and Innovation (TEKES) granted BioMediTech 
the research programme, Human Spare Parts, which is still going on. Through 
this research programme, RM research in Tampere has continued to advance. 
As all initiatives have aimed to strengthen the biotechnology cluster in 
Finland and in Tampere, RM applications in particular were seen as a strength 
in which other competencies could be utilized. 
Industrial sphere
The emergent RM cluster in Tampere includes many potential application areas 
in stem cell therapies, diagnostics and supporting technologies. Even though 
the financial need might be too high for stem cell therapies in relation to readily 
available funding resources, there are still possibilities for other supporting 
technologies and diagnostics, for example. In the Tampere region, only a 
few firms purely focus on stem cell-related services or products and the RM-
focused industrial sphere is in a very embryonic formation phase. In life science 
fields, such as devices, ICT, biomaterials, pharma, and services, there are firms 
focusing on biomaterials and cell-related technologies, and, traditionally, 
health and biotechnology industries have been successful in Tampere. There 
have been few initial public offerings from Tampere in the biotechnology sector. 
One was in 1997 to the New York stock exchange and the other was in 2004 to 
the London stock exchange, even though experience from these did not really 
stimulate the growth of the local ecosystem on a large scale.
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Regarding cluster development in the RM sector, there have been only 
a few small firms in Tampere dealing with stem cells. However, the Tampere 
region still has some potential firms in the biotechnology industry that could 
acquire potential RM-related applications and innovations from BioMediTech 
in later phases of cluster development. In this sphere, there have been over 
10 spin-offs from the research groups in Tampere. The good thing for the 
local industrial sphere is that BioMediTech actively seeks opportunities to 
commercialize their research, and for this purpose they have established 
several internal projects. However, currently there are no active connections 
between small local firms and BioMediTech in order to exploit the potential 
applications BioMediTech has developed. Instead, BioMediTech seeks 
partners from established bigger companies abroad.
Therapy development is expensive in the RM sector and both BioMediTech 
and their stakeholders have acknowledged this. Around 2008, there was a 
plan to establish the Hospital of Advanced Therapies (HAT) to provide those 
therapies that Regea (predecessor of BioMediTech) was developing at that 
time, but eventually the implementation of HAT was suspended. BioMediTech 
has continued to deliver bone growth therapies through the hospital, though, 
and the university has planned to start a preclinical study to prepare official 
clinical trials in collaboration with other organizations. This therapy has 
in many ways been instrumental in this formation phase of the emergent 
RM cluster in Tampere, as it has shown the benefits that RM therapies can 
provide to patients, and has given proof to and hope for actors that there are 
possibilities in this sphere. It is very important for the potential development 
phase of this cluster that this therapy, as well as other potential therapies, will 
be transferred at some point to companies that have a link to the Tampere 
region. As suggested in the competence bloc theory, an entrepreneurial firm 
is most likely to carry potential innovation at the beginning and then later an 
established firm is likely to acquire it. Hence, it is important that BioMediTech 
also actively seeks connections to established companies and in that way 
make the Tampere region known to the potential industrialists. However, at 
the same time there is a need for local start-ups that can acquire innovations 
from BioMediTech, but also strengthen the competence bloc in the Tampere 
region in order to shape the way for the development phase of the cluster. 
The Finnish market for all potential products is small, locally, and firms 
must look towards international markets to find customers. As one of the 
interviewees in the university said: “Whatever products we start to produce 
here, the market is global”. Thus, international conferences are important 
for practitioners, being places where it is possible to see in what direction 
the field is heading. It also means that patenting must be done wisely 
and rationally with regard to potential markets. This brings challenges for 
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BioMediTech (and all the universities) as they have to make choices as to what 
to patent and where. There is also a tension between scientific publications 
and patenting, which in some cases forces universities to patent too early so 
that researchers are able to publish their work. Potential market for products 
is the key thing for firms, and especially in the cases where university research 
is transferred to start-ups or existing firms. It is important for the emergent 
RM cluster in Tampere that potential firms are going to stay in the region 
and establish a manufacturing function. The development of a cluster might 
be the reason why firms choose to stay in Finland, even though the cost of 
manufacturing might be relatively high. It is important for local firms that 
they have the possibility to scale-up their production. However, currently 
the local competence bloc lacks industrialists but also related services like 
companies that can help to scale up the cell production. It is important for 
the process from the formation phase to the development phase of a cluster, 
such as the current science-based emergent RM cluster, that the emergence 
of local businesses and supporting services happens simultaneously. Locally 
there is also a need for a stronger interface structure between industry and 
academia in the RM fields. 
Demand
Multi-level demand has been the most important aspect in this formation 
phase of the emergent RM cluster in Tampere. One of the other most 
important aspects is that real patients have been treated with bone growth 
therapy. This therapy is for patients’ benefit, and in the end it is patients who 
create a demand for new RM therapies in general. In health care, however, 
hospitals and clinicians are the main actors who make decisions about the use 
of new therapies in patient care. Hence, clinicians contribute to this demand 
as well. This has also been the case in Tampere, as the clinical need has been 
the driving force for RM therapies and research and hospitals have been very 
active in creating the demand for this experimental therapy, which has not 
undergone any official clinical trials yet. As the development of RM therapies 
needs specialized tools, it also creates a demand. Solutions in the market are 
not always sufficient, and, hence, stem cell biology groups within academia 
have created a demand for better tools. As BioMediTech is a joint institute 
of two universities and there are research groups with technical disciplines 
in the Human Spare Parts programme, technology groups have been able 
to provide solutions to this internal demand from stem cell groups. In most 
industries, firms are the manufacturers of products and services. Here this is 
not yet the case. Instead, the universities and hospitals have been the main 
actors in the development of the new therapy and providing it to patients. In 
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order to proceed to the development phase of the RM cluster, the industrial 
sphere must take the lead.
The situation is currently positive in terms of new potential commercial 
offerings either for start-ups or established companies. Innovations created 
in BioMediTech (both tools and therapies) cannot be commercialized and 
brought to full-scale production without firms, and as scientific development 
advances, it will create more demand for different tools. Similarly, 
development of therapies requires full-scale production solutions. Hence, it 
seems that there are possibilities for the transition from the formation phase 
to the development phase of the cluster. However, for the future, an important 
question is whether the demand will grow big enough to attract investors 
and firms as well. Customers are in a key position in this as they create such 
a demand. Now academia is a customer for itself, but in the future, other 
customers will also be needed in order to develop the competence bloc.
Education and research
As in any university, education and research are two pillars in BioMediTech. 
There is also a third strong pillar, which is innovation promotion. Innovation 
is the key factor for possibilities for future economic activity in the RM sector 
in Tampere. As not all graduates are able to continue their studies as PhD 
students, the need for jobs is high and the supply of competent employees 
is secured. Regarding research, in recent years, one of the biggest research 
programmes in Tampere has been the Human Spare Parts research programme. 
In this programme, Tampere University of Technology and the University of 
Tampere combined their expertise in supporting technologies and stem cell 
biology. Together four groups from the field of technology and four groups 
from the field of stem cells joined the programme, in which the focus was on 
the advancement of health care with new therapies and solutions. In general, 
research groups in BioMediTech have a high rate of international collaboration. 
The combination of stem cell research and technology expertise is 
important in advancing the RM sector. Because of this, it is possible to develop 
highly specialized solutions for stem cell research that are otherwise very 
difficult to find in the technology market. As these solutions have emerged 
from the research of BioMediTech, there are also other potential users for 
them, which creates opportunities for firms to grow and expand their product 
portfolio. The advantage is that researchers have already tested these new 
technological tools in practical work situations. These technologies are highly 
necessary in stem cell research and in subsequent applications. Hence, these 
form an important industry in the RM cluster, where other research groups in 
the RM sector are also potential customers internationally. 
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Hospitals are important in the RM sector, and research groups work in 
close collaboration with clinicians and hospitals, because this is the most 
efficient way to direct the research along the right path. The combination 
of university and hospital is also essential in order to provide bone growth 
therapy for patients. Currently, with regard to the utilized bone growth 
therapy, bone products are made in the university’s clean room. From there 
the products are transferred to the hospital where hospital staff conduct 
clinical operations for patients. Without this close connection, it would 
be very difficult to see whether potential treatment really works. It is also 
beneficial for firms, as hospitals are experienced in working with stem cell-
based products, which makes it easier for firms to approach them.
The interface structure between industry and academia is a part of the 
operations in BioMediTech as they approach industry directly. An important 
aspect in the emergence of the RM cluster in Tampere is the development of 
a proof of concepts (PoC) from the research of BioMediTech. With the PoC 
approach, BioMediTech is able to reduce the risk of failure in the technology 
transfer phase (Heinonen, 2015). According to an interviewee: "it is wise 
to stay in the university and conduct research, and progress until there is 
a clinical proof of concept". The development of PoCs is an efficient tool 
by which it is possible to combine technology and experience in the same 
package and transfer it to a firm. As the university is conducting the initial 
market studies and developing working prototypes, it is easier for firms to 
continue the development and be more prepared to exploit innovations 
commercially as well.
Legal and political sphere
BioMediTech and other organizations as well as firms, are part of the Finnish 
innovation system. This system consists of several organizations that are 
interlinked with each other. According to Kotiranta et al. (2009), even though 
there are several public organizations embedded in the national innovation 
system, only a few of them are relevant to the firms. Among those relevant 
organizations, the Technical Research Center of Finland (VTT) is relevant for 
large companies, and for all companies, universities and the Finnish Funding 
Agency for Technology and Innovation (TEKES) are relevant, according to the 
survey made by The Research Institute of the Finnish Economy (Kotiranta et 
al., 2009). Initiatives in Tampere are in line with the overall Finnish national 
innovation policy, which is rather technology-driven (Kotiranta et al., 2009). 
At ministry level, initiatives and actions are dependent on the political system, 
which also has implications at a governmental organization level. Hence, 
elections could radically change the chosen path. However, in Tampere the 
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exception was, as discussed in section 5.3 about demand, that clinical need 
triggered the scientific advances and the development of needed solutions. 
From the outset, regional actors have understood that to be in the front 
line, scientific and development efforts need to be focused, and one of the 
results of this was the establishment of BioMediTech and the Human Spare 
Parts research programme. Regional initiatives have had a strong influence 
and significance, and in a sense, the development of potential innovations 
was a bottom-up process that was first supported by regional development 
agencies and later by national-level innovation agencies. 
In general, new therapies in the RM sector need to fulfil the regulatory 
requirements, including clinical trials, which has direct implications for 
both emerging firms and existing firms hoping to develop in the field of RM 
therapies. In the EU, it is possible to deliver RM therapies under a special 
ATMP hospital exemption, in which there is no need for clinical trials. National 
authorities are able to decide how many treatments it is possible to deliver 
with hospital exemption, and in Finland there is no strict limit in place. The 
ATMP hospital exemption is beneficial for the emergence of the RM sector in 
the EU, but for firms it is contradictory, as it makes it possible for governments 
to provide RM therapies with no clinical trials, and at the same time firms need 
to fulfil strict regulative requirements in order to exploit these commercially. 
In Tampere, ATMP hospital exemption is the way to provide treatments with 
bone growth innovation in RM. With regard to this therapy, there are plans 
to conduct official clinical trials in order to commercialize it. As regulatory 
approval is essential for new therapies, BioMediTech has a close connection 
with regulators in order to find a way to fulfil all requirements correctly. 
Even more, as one interviewee in BioMediTech said: “regulation has actually 
provided help to us”. Without regulation there would be always a little 
uncertainty how things should be done, and clear and efficient regulation 
might be a facilitator of medical innovation (Messenger & Tomlins, 2011). As 
the RM sector includes different technologies, not all of them are regulated 
as highly as stem cell therapies. Products that are solely for research purposes 
are not regulated at all. This enables technology transfer from BioMediTech 
to firms to take place more easily and faster.
Apart from developed technologies, use of the technologies also has 
consequences and challenges that are worth mentioning. For instance, it 
was essential for the first operations with regard to bone growth therapy, 
that the board of directors in the local hospital agreed and gave permission 
to conduct experimental treatment for patients (Mesimäki et al., 2009). 
However, the GMP level laboratory is crucial in the cases where cells for 
human treatment are prepared and, luckily, the GMP level laboratory and 
clean rooms were already in existence at the time of the first patients being 
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treated. In Finland, in those cases where clinicians did everything carefully, 
individual clinicians are not alone responsible if something goes wrong. This 
is an advantage for experimental therapies, as clinicians have more courage 
to perform operations. There are neither problems with public opinion nor 
high debate regarding their ethicality, which is very favorable for the use of 
stem cells in therapies.
Funding
Public funding is a key factor in the development of the RM sector in general, 
and specifically in the formation phase of the local cluster. In addition to 
the normal funding universities seek and receive for research, Regea and 
BioMediTech have received much public funding from TEKES, the Academy 
of Finland, the Council of Tampere Region, and the City of Tampere in order 
to develop the RM sphere in Tampere. For example, the Council of Tampere 
Region has provided funding for research facilities that have affected 
positively the progress in RM research. In 2011, BioMediTech received 10 
million euros in funding from TEKES for the Human Spare Parts research 
programme for the years 2011–2014, which boosted the formation phase of 
the RM cluster in Tampere region significantly. Lately, TEKES granted another 
4.5 million euros for the years 2015–2016. This basic funding for the Human 
Spare Parts research programme has made it possible to focus on long-term 
goals and strengthen collaborative structures between research groups. 
The advantageous aspect for BioMediTech has been that TEKES funds 
PoC projects in order to facilitate technology transfer from university to 
industry. This allows BioMediTech to focus research commercialization on 
distinct projects that do not affect research projects too much. However, due 
to stable funding, it is possible in some cases to revert the PoC back to the 
research programme in order to develop it further. For future products that 
are based on university research, PoC development is essential. It is important 
to assess the market potential of these potential products, in order to transfer 
successfully innovation to industry. As PoC development is important, TEKES 
provides a financial instrument with which to achieve it. However, as stem 
cell products require long clinical trials, the financial aid that TEKES provides is 
not perfectly suitable, as TEKES requires faster outcomes, which are possible 
in the case of technological solutions. Even though RM cell therapy products 
are not suitable for PoC funding from TEKES, they are willing to support 
commercialization efforts in other ways. For example, with regard to bone 
growth therapy, there are plans to conduct studies toward clinical trials in 
collaboration with external partners and TEKES is willing to help financially in 
this process. However, for the development of RM therapies, it is particularly 
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important to have an endowment from which early clinical trials are funded 
in academia, as firms are unlikely to receive venture capital funding for 
early clinical trials, which are needed for a product to be approved. As one 
interviewee mentioned: “you can't establish a firm in too early stage. It is 
really expensive to operate a firm in this field, and it is the reason why venture 
capital is needed at some point". However, to conduct clinical trials in the 
university requires a lot of expertise and resources. Even though it is possible 
to develop products for scientific use at a much faster pace, for the future of 
the RM sector globally and related clusters, RM therapies are crucial.
Conclusions and implications
Prerequisite for the emergence of an RM cluster in Tampere is that academia 
is able to generate enough new knowledge and innovations for firms to use. 
A growing number of firms are able to exploit university-based innovations, 
which could lead to the emergence and growth of local firms. The RM sector 
requires multiple technology disciplines, which means that there might be 
several opportunities for firms to diversify. This eventually should lead the 
emergent cluster to a growth path due to the emergence of new firms and 
the growth (diversification) of existing firms, which subsequently leads to 
a situation where existing firms need new suppliers and service providers. 
The competence bloc in this process describes well how new firms emerge 
in the region and what it required. In the formation phase it seems to be 
especially important to get bigger companies involved as well, as those can 
act as industrialists for new companies later. The availability of industrialists 
is beneficial for both entrepreneurs and venture capitalists. 
The main implications for policymakers concern requirements that 
are evidently important for the emergence of a science-based cluster and 
its further development from the formation phase to development phase. 
First, public funding is extremely important, as in the beginning there is no 
company structure investing in the future. A local cluster needs regionally 
specified funding schemes in order to conduct research in academia, but also 
to develop research-based innovations that can be transferred to companies. 
There should be appropriate funding to conduct early clinical trials in the 
universities as well, but it is also important to support the collaboration with 
industry from the very early phases of innovation. Second, collaboration 
among local agents (both public and private) is necessary in order to exploit 
fully the capacity in the region by, for instance, avoiding duplicity of efforts 
from related firms in undertaking a research/innovation project. International 
collaborations are also highly important in allowing learning, applying 
funding, and providing a wider demand, to mention just some examples. 
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Third, a growing number of firms is especially important for the local cluster. 
The science-based sector analysed here does not completely fit within the 
so-called linear model of innovation. On the contrary, it requires a complex 
interaction and prototyping between relevant actors. Therefore, the growth 
of firms might be supported by encouraging a practice-oriented environment 
and hence the use of emerging innovations would be more plausible.
In this study, some major challenges are pointed out regarding an 
emergent cluster, which call for tailor-made socio-economic policies at 
the meso-level. Science-based clusters obviously need tailored policies, as 
sectors are different, but related. Specific policies are also needed in different 
stages of the cluster life cycle, especially for an emergent cluster to proceed 
from the formation to the development phase and finally to become a 
matured cluster. With regard to the emergent RM cluster in Tampere, the 
development process is long and it might take still years to actually proceed 
from the formation phase to the development phase.  
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Abstrakt (in Polish)
Klastry są istotnym elementem regionalnych gospodarek, a rozwijające się klastry 
mają szczególne znaczenie dla dywersyfikacji działalności gospodarczej poprzez 
nowe technologie i branże. Branże oparte na nauce są w tej dziedzinie szczególnie 
obiecujące dla tworzenia i wsparcia wizji rozwoju określonych terytoriów, dzięki 
innowacjom przełomowym lub wzbogaceniu obecnych modeli gospodarczych, 
działających w tradycyjnych sektorach. Branża medycyny regeneracyjnej (MR) 
stanowi przykład takich wyłaniających się klastrów. Branża ta jest silnie zależna od 
badań naukowych, co oznacza, że region musi inwestować w badania naukowe w tej 
dziedzinie, by spodziewać się określonego zwrotu z inwestycji. Regiony zazwyczaj nie 
posiadają rozwiniętych klastrów w dziedzinie MR, stąd branże te powinny wyłonić się 
z istniejących dziedzin działalności lub poszerzyć obecne sektory. Medycyna regen­
eracyjna angażuje szeroki zestaw technologii i sektorów, które mogą tworzyć klaster 
i korzystać z jego efektów, jeśli projekt odniesie sukces. W artykule zrealizowano dwa 
cele. Po pierwsze, przedstawiono bariery, które ograniczają rozwój młodych klastrów. 
Po drugie, określono w jaki sposób w klastrach tego rodzaju powstają innowacje i 
jakie jest ich znaczenie dla danego terytorium. Na podstawie przeglądu literatury 
przedstawiono rynek technologii i komercjalizacji w sektorze MR. Badanie empiry­
czne oparto na rozwijającym się klastrze MR w regionie Tampere, w Finlandii. Na 
podstawie 24 wywiadów przedstawiono kontekst tworzenia klastra w Tampere, gdzie 
sfera nauki inspiruje i stymuluje rozwój tej branży. Jednym z celów uniwersytetu jest 
komercjalizacja badań w dziedzinie MR, jakkolwiek  na razie brak komercyjnych re­
zultatów. Badanie ma znaczenie dla zrozumienia rozwoju młodego klastra w branży 
opartej na nauce, w fazie zalążkowej i na wczesnych etapach rozwoju. Wskazano 
główne wyzwania dla powstającego klastra, które to wyzwania wymagają dostoso­
wania polityki wsparcia na poziomie mezo-ekonomicznym. Dla klastrów opartych na 
wiedzy niezbędna jest ukierunkowana polityka, a określone sektory, na danym etapie 
rozwoju potrzebują specyficznych narzędzi polityki, aby osiągnąć fazę dojrzałości. 
Słowa kluczowe: medycyna regeneracyjna, wyłaniający się klaster, komercjalizacja, 
innowacja, blok kompetencji, rynek technologii.
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